<DOC>
	<DOC>NCT02521649</DOC>
	<brief_summary>An open, dose-ranging, multiple dose, multi-centre study in patients with Stage I-III or Stage IV gastric cancer. Twelve patients in each of 5 treatment groups were to receive three injections at weeks 0, 2 and 6 with provision for a single booster injection in an extension study period.</brief_summary>
	<brief_title>Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Stage IIII Criteria Patients aged 18 years or over who had had a macroscopically curative resection for gastric adenocarcinoma. Absence of metastatic disease evident from: physical examination the most recent chest Xray abdominal CT or ultrasound scan Life expectancy of at least 3 months WHO performance status of 0 to 1 Written informed consent given Stage IV Criteria Patients aged 18 years or over with Stage IV gastric cancer: carcinoma with the primary tumour invading the adjacent structures and/or involvement of more than 15 regional lymph nodes and/or distant metastases Life expectancy of at least 3 months WHO performance status of 0 to 2 Written informed consent given History of other malignant disease except nonmelanomatous skin cancer or in situ carcinoma of the uterine cervix Recurrent gastric cancer following previous surgery Presence of metastatic disease: peritoneal deposits or involved lymph nodes outside the limit of resection Previous use, concomitant use or anticipated use in the period of the study, of any anticancer therapies Concomitant use of immunosuppressants, including systemic (ie oral or injected) corticosteroids Females who were pregnant, planning to become pregnant or lactating Patients who were taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or during this study Previous G17DT treatment Haematological indicators: Haemoglobin &lt;10.0g/dl White blood cell count &lt;4.0 x 109/l Platelets &lt;100 x 109/l</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>G17DT</keyword>
	<keyword>PAS</keyword>
	<keyword>Insegia</keyword>
	<keyword>Gastrimmune</keyword>
</DOC>